Atlas Trials

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

Clinical trial NCT05871021 · RECRUITING

Trial details

NCT number
NCT05871021
Sponsor
University Hospital Tuebingen
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Glioblastoma
Start date
2024-04-10
Primary completion
2028-04-10
Enrollment
146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.